Equity · Healthcare
RLMD
NASDAQRelmada Therapeutics (RLMD)
This price chart is drawn by TradingView, from their own data, in an embed loaded from their servers. We hold too few licensed daily closes of our own for RLMD to draw a line in its place.
- Market cap
- 557.3M USD
- EPS, diluted, year to Dec 2025
- −1.45 USD
- 52-week range
- 0.563 USD – 7.88 USD
- Avg volume
- 526.2K
as of Jul 17, 2026
Have Relmada Therapeutics (RLMD) insiders bought or sold shares recently?
In the 90 days to 1 Nov 2026, Relmada Therapeutics insiders reported 4 open-market purchases and no sales (SEC Form 4).
Form 4, 90 days to 1 Nov 2026, newest reported trade 10 Sep 2026
Buys 4Sells 0Net bought $1.67MOther filings 0
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 10 Sep 2026 | Shenouda MagedChief Financial Officer | Buy | 79,800 | 339K USD |
| 10 Sep 2026 | TRAVERSA SERGIOChief Executive Officer | Buy | 100,000 | 410K USD |
| 09 Sep 2026 | Shenouda MagedChief Financial Officer | Buy | 120,200 | 505K USD |
| 09 Sep 2026 | TRAVERSA SERGIOChief Executive Officer | Buy | 100,000 | 418K USD |
| Bought | 4 open-market purchases | 400,000 | $1.67M |
Which funds hold Relmada Therapeutics (RLMD)?
7 of the 45 institutional funds we track reported a Relmada Therapeutics position for the quarter ended 30 Jun 2026 — a combined 52.4M USD; the latest of those filings landed 02 Sep 2026.
| Fund | Position | Shares | Value | Shares q/q |
|---|---|---|---|---|
| Millennium Management | Trimmed | 2,361,827 | 16.3M USD | −39.6% |
| Marshall Wace | Trimmed | 2,246,839 | 15.5M USD | −49.9% |
| Balyasny Asset Management | Added | 1,520,688 | 10.5M USD | +502.4% |
| Citadel Advisors | New position | 1,061,665 | 7.3M USD | |
| Two Sigma Investments | Trimmed | 214,915 | 1.5M USD | −47.3% |
| D. E. Shaw & Co. | New position | 109,474 | 758K USD | |
| Renaissance Technologies | Trimmed | 57,800 | 400K USD | −65.4% |
| Point72 Asset Management | Exited |
Have members of Congress traded Relmada Therapeutics (RLMD)?
The most recent congressional trade disclosed in Relmada Therapeutics is a sale by Sara Jacobs (house, CA), dated 12 Dec 2022.
STOCK Act disclosures
| Traded | Member | Type | Amount | Filed after |
|---|---|---|---|---|
| 12 Dec 2022 | Sara Jacobshouse · Democrat–CA | Sale | 1K USD–15K USD | 39 days |
| 08 Nov 2022 | Sara Jacobshouse · Democrat–CA | Purchase | 1K USD–15K USD | 34 days |
What has been filed or recorded for Relmada Therapeutics (RLMD)?
The filings we hold for Relmada Therapeutics, newest first: 2 fails-to-deliver days, 6 quarterly earnings reports, 2 annual reports and 4 reported financial figures, the latest dated 09 Oct 2026. No next earnings date is announced in SEC filings yet.
| And | ||||
|---|---|---|---|---|
| 09 Oct 2026 | Fails to deliver | Shares failed to deliver | 300,758 shares | 953K USD notional · 0.282% of shares out |
| 06 Oct 2026 | Fails to deliver | Shares failed to deliver | 1,900 shares | 7K USD notional · 0.002% of shares out |
| 30 Jun 2026 | Quarterly earnings | Q2 2026 reported | EPS −0.11 USD | |
| 30 Jun 2026 | Financials | Total assets | 219.1M USD | at period end |
| 30 Jun 2026 | Financials | Total equity | 206.6M USD | at period end |
| 31 Mar 2026 | Quarterly earnings | Q1 2026 reported | EPS −0.22 USD | |
| 31 Dec 2025 | Annual report | FY 2025 reported | EPS −1.45 USD | |
| 31 Dec 2025 | Financials | Net income | −57.4M USD | fiscal year |
| 31 Dec 2025 | Financials | Diluted EPS | −1.45 USD | fiscal year |
| 30 Sep 2025 | Quarterly earnings | Q3 2025 reported | EPS −0.30 USD | |
| 30 Jun 2025 | Quarterly earnings | Q2 2025 reported | EPS −0.30 USD | |
| 31 Mar 2025 | Quarterly earnings | Q1 2025 reported | EPS −0.58 USD | |
| 31 Dec 2024 | Annual report | FY 2024 reported | EPS −2.65 USD | |
| 30 Sep 2024 | Quarterly earnings | Q3 2024 reported | EPS −0.72 USD |
Relmada Therapeutics (RLMD): frequently asked questions
What is Relmada Therapeutics’ market cap?
Relmada Therapeutics is worth 557.3M USD by market value as of 17 Jul 2026, which is the share price times the shares on issue from its SEC filings.
Have Relmada Therapeutics insiders bought or sold shares recently?
In the 90 days to 1 Nov 2026, Relmada Therapeutics insiders reported 4 open-market purchases and no sales (SEC Form 4). See Insiders
Which funds own Relmada Therapeutics?
7 of the 45 funds we track reported a Relmada Therapeutics position for the quarter ended 30 Jun 2026, per their SEC Form 13F filings. The largest reported positions were Millennium Management, Marshall Wace and Balyasny Asset Management. See Funds
Have members of Congress traded Relmada Therapeutics?
Yes. 2 trades in Relmada Therapeutics appear in the congressional disclosures we hold; the latest is a sale by Sara Jacobs (House, CA) dated 12 Dec 2022, filed 20 Jan 2023. Amounts are disclosed as ranges, and a filing can follow the trade by up to 45 days. See Congress
When did Relmada Therapeutics last report earnings?
Relmada Therapeutics last reported earnings on 30 Jun 2026 for Q2 2026, with EPS of −0.11 USD; no next date is announced in SEC filings yet. See Filings
Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.
References
- Finazonprior-day close, indicative (IEX-derived, not the official close)
- TradingViewthe price chart widget, drawn by TradingView from their own data
- SEC EDGARForm 4 filings (insider transactions)
- SEC EDGAR13F filings
- House disclosuresU.S. House of Representatives financial disclosures
- SECSEC fails-to-deliver (CNS) data
- SEC EDGARXBRL company facts, latest period ended 30 Jun 2026
- SEC EDGARreported earnings figures and scheduled report dates
- SEC EDGARValuation computed from SEC EDGAR filings